For traders looking to scale their trading with real capital, the moment has arrived. The Direct Funded Trader $200,000 Two Step Challenge in partnership with FXAN is now available at an exclusive 60% discount, but this offer is only valid until Sunday, November 30 at 23:59 CE(S)T. This is a rare opportunity to access significant funding on a platform widely trusted by professional traders worldwide.
Normally priced at €279.99, the challenge is now available for just €112 by using the code DFT60 at checkout. For those serious about taking their trading to the next level, this is one of the most powerful upgrades currently available. Traders will not only gain access to a $200,000 account but also the chance to trade on MetaTrader 5, a platform renowned for its advanced tools, reliability, and global acceptance.
FXAN & Exclusive $200K Direct Funded Trader Discount
When you enroll through FXAN, you will also receive exclusive educational materials to help you get the most out of your trading experience. These resources are here to provide a strong foundation in using the platform, understanding the tools, and preparing for more advanced strategies if you decide to continue with a monthly FXAN plan.
- This offer is limited to one $200K challenge per person.
- Traders who have previously completed a $100K or $5K Direct Funded Trader challenge are still eligible for this offer.
- It is not possible to receive multiple $200K challenges.
This offer represents one of the most compelling opportunities in prop trading right now. By securing this challenge, traders gain access to high-level funding at a fraction of the regular cost, with the added advantage of educational support to help improve their skills and performance.
Secure your $200K MT5 Challenge today: FXAN Direct Funded Trader $200K Challenge
Act fast: this exclusive offer ends Sunday, November 30 at 23:59 CE(S)T. Don’t miss your chance to step up your trading game and access a $200,000 account at a 60% discount.
Also, don’t forget to read the Review about the Firm.
